Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 5/2013

Open Access 01-10-2013 | Research article

Differential expression of CD148 on leukocyte subsets in inflammatory arthritis

Authors: Richa K Dave, Amy J Naylor, Stephen P Young, Rachel Bayley, Debbie L Hardie, Oliver Haworth, David A Rider, Andrew D Cook, Christopher D Buckley, Stuart Kellie

Published in: Arthritis Research & Therapy | Issue 5/2013

Login to get access

Abstract

Introduction

Monocytic cells play a central role in the aetiology of rheumatoid arthritis, and manipulation of the activation of these cells is an approach currently under investigation to discover new therapies for this and associated diseases. CD148 is a transmembrane tyrosine phosphatase that is highly expressed in monocytes and macrophages and, since this family of molecules plays an important role in the regulation of cell activity, CD148 is a potential target for the manipulation of macrophage activation. For any molecule to be considered a therapeutic target, it is important for it to be increased in activity or expression during disease.

Methods

We have investigated the expression of CD148 in two murine models of arthritis and in joints from rheumatoid arthritis (RA) patients using real-time PCR, immunohistochemistry, and studied the effects of proinflammatory stimuli on CD148 activity using biochemical assays.

Results

We report that CD148 mRNA is upregulated in diseased joints of mice with collagen-induced arthritis. Furthermore, we report that in mice CD148 protein is highly expressed in infiltrating monocytes of diseased joints, with a small fraction of T cells also expressing CD148. In human arthritic joints both T cells and monocytes expressed high levels of CD148, however, we show differential expression of CD148 in T cells and monocytes from normal human peripheral blood compared to peripheral blood from RA and both normal and RA synovial fluid. Finally, we show that synovial fluid from rheumatoid arthritis patients suppresses CD148 phosphatase activity.

Conclusions

CD148 is upregulated in macrophages and T cells in human RA samples, and its activity is enhanced by treatment with tumour necrosis factor alpha (TNFα), and reduced by synovial fluid or oxidising conditions. A greater understanding of the role of CD148 in chronic inflammation may lead to alternative therapeutic approaches to these diseases.
Appendix
Available only for authorised users
Literature
1.
Stoy N: Macrophage biology and pathobiology in the evolution of immune responses: A functional analysis. Pathobiology. 2001, 69: 179-211. 10.1159/000055944.CrossRefPubMed
2.
Gordon S, Martinez FO: Alternative activation of macrophages: mechanism and functions. Immunity. 2010, 32: 593-604. 10.1016/j.immuni.2010.05.007.CrossRefPubMed
3.
Geissmann F, Gordon S, Hume DA, Mowat AM, Randolph GJ: Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol. 2010, 10: 453-460. 10.1038/nri2784.PubMedCentralCrossRefPubMed
4.
Hamilton JA: Nondisposable materials, chronic inflammation, and adjuvant action. J Leukoc Biol. 2003, 73: 702-712. 10.1189/jlb.0103037.CrossRefPubMed
5.
Shanley TP: Phosphatases: counterregulatory role in inflammatory cell signaling. Crit Care Med. 2002, 30: S80-S88. 10.1097/00003246-200201001-00011.CrossRef
6.
Weiss A: Kinases and phosphatases of the immune system. Immunol Rev. 2009, 228: 5-8. 10.1111/j.1600-065X.2009.00761.x.CrossRefPubMed
7.
Smith JL, Schaffner AE, Hofmeister JK, Hartman M, Wei G, Forsthoefel D, Hume DA, Ostrowski MC: ets-2 is a target for an Akt (protein kinase B)/Jun N-terminal kinase signaling pathway in macrophages of motheaten-viable mutant mice. Mol Cell Biol. 2000, 20: 8026-8034. 10.1128/MCB.20.21.8026-8034.2000.PubMedCentralCrossRefPubMed
8.
Shultz LD, Rajan TV, Greiner DL: Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency. Trends Biotechnol. 1997, 15: 302-307. 10.1016/S0167-7799(97)01060-3.CrossRefPubMed
9.
Ostman A, Yang Q, Tonks NK: Expression of DEP-1, a receptor-like protein-tyrosine phosphatase, is enhanced with increasing cell density. Proc Natl Acad Sci USA. 1994, 91: 9680-9684. 10.1073/pnas.91.21.9680.PubMedCentralCrossRefPubMed
10.
Gaya A, Pirotto F, Palou E, Autschbach F, Del Pozo V, Sole J, Serra-Pages C: CD148, a new membrane tyrosine phosphatase involved in leukocyte function. Leuk Lymphoma. 1999, 35: 237-243. 10.3109/10428199909145726.CrossRefPubMed
11.
Lin J, Zhu JW, Baker JE, Weiss A: Regulated expression of the receptor-like tyrosine phosphatase CD148 on hemopoietic cells. J Immunol. 2004, 173: 2324-2330.CrossRefPubMed
12.
Iuliano R, Trapasso F, Le Pera I, Schepis F, Sama I, Clodomiro A, Dumon KR, Santoro M, Chiariotti L, Viglietto G, Fusco A: An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo. Cancer Res. 2003, 63: 882-886.PubMed
13.
Keane MM, Lowrey GA, Ettenberg SA, Dayton MA, Lipkowitz S: The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells. Cancer Res. 1996, 56: 4236-4243.PubMed
14.
Le Pera I, Iuliano R, Florio T, Susini C, Trapasso F, Santoro M, Chiariotti L, Schettini G, Viglietto G, Fusco A: The rat tyrosine phosphatase eta increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue. Oncogene. 2005, 24: 3187-3195. 10.1038/sj.onc.1208510.CrossRef
15.
Stepanek O, Kalina T, Draber P, Skopcova T, Svojgr K, Angelisova P, Horejsi V, Weiss A, Brdicka T: Regulation of Src family kinases involved in T cell receptor signaling by protein-tyrosine phosphatase CD148. J Biol Chem. 2011, 286: 22101-22112. 10.1074/jbc.M110.196733.PubMedCentralCrossRefPubMed
16.
Zhu JW, Brdicka T, Katsumoto TR, Lin J, Weiss A: Structurally distinct Phosphatases CD45 and CD148 both regulate B cell and macrophage immunoreceptor signaling. Immunity. 2008, 28: 183-196. 10.1016/j.immuni.2007.11.024.PubMedCentralCrossRefPubMed
17.
Kovalenko M, Denner K, Sandstrom J, Persson C, Gross S, Jandt E, Vilella R, Bohmer F, Ostman A: Site-selective dephosphorylation of the platelet-derived growth factor beta-receptor by the receptor-like protein-tyrosine phosphatase DEP-1. J Biol Chem. 2000, 275: 16219-16226. 10.1074/jbc.275.21.16219.CrossRefPubMed
18.
Palka HL, Park M, Tonks NK: Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1. J Biol Chem. 2003, 278: 5728-5735. 10.1074/jbc.M210656200.CrossRefPubMed
19.
Lampugnani MG, Orsenigo F, Gagliani MC, Tacchetti C, Dejana E: Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J Cell Biol. 2006, 174: 593-604. 10.1083/jcb.200602080.PubMedCentralCrossRefPubMed
20.
Spring K, Chabot C, Langlois S, Lapointe L, Trinh NT, Caron C, Hebda JK, Gavard J, Elchebly M, Royal I: Tyrosine phosphorylation of DEP-1/CD148 as a mechanism controlling Src kinase activation, endothelial cell permeability, invasion, and capillary formation. Blood. 2012, 120: 2745-2756. 10.1182/blood-2011-12-398040.CrossRefPubMed
21.
Tsuboi N, Utsunomiya T, Roberts RL, Ito H, Takahashi K, Noda M, Takahashi T: The tyrosine phosphatase CD148 interacts with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem J. 2008, 413: 193-200. 10.1042/BJ20071317.CrossRefPubMed
22.
Senis YA, Tomlinson MG, Ellison S, Mazharian A, Lim J, Zhao Y, Kornerup KN, Auger JM, Thomas SG, Dhanjal T, Kalia N, Zhu JW, Weiss A, Watson Sp: The tyrosine phosphatase CD148 is an essential positive regulator of platelet activation and thrombosis. Blood. 2009, 113: 4942-4954. 10.1182/blood-2008-08-174318.PubMedCentralCrossRefPubMed
23.
Holsinger LJ, Ward K, Duffield B, Zachwieja J, Jallal B: The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn). Oncogene. 2002, 21: 7067-7076. 10.1038/sj.onc.1205858.CrossRefPubMed
24.
Sallee JL, Burridge K: Density-enhanced phosphatase 1 regulates phosphorylation of tight junction proteins and enhances barrier function of epithelial cells. J Biol Chem. 2009, 284: 14997-15006. 10.1074/jbc.M901901200.PubMedCentralCrossRefPubMed
25.
Grazia Lampugnani M, Zanetti A, Corada M, Takahashi T, Balconi G, Breviario F, Orsenigo F, Cattelino A, Kemler R, Daniel TO, Dejana E: Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148. J Cell Biol. 2003, 16: 793-804.CrossRef
26.
Keane MM, Lowrey GA, Ettenberg SA, Dayton MA, Lipkowitz S: The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells. Cancer Res. 1996, 56: 4236-4243.PubMed
27.
Kellie S, Craggs G, Bird IN, Jones GE: The tyrosine phosphatase DEP-1 induces cytoskeletal rearrangements, aberrant cell-substratum interactions and a reduction in cell proliferation. J Cell Sc. 2004, 11: 609-618.CrossRef
28.
Dave RK, Hume DA, Elsegood C, Kellie S: CD148/DEP-1 association with areas of cytoskeletal organisation in macrophages. Exp Cell Res. 2009, 315: 1734-1744. 10.1016/j.yexcr.2009.02.023.CrossRefPubMed
29.
Osborne JM, den Elzen N, Lichanska AM, Costelloe EO, Yamada T, Cassady AI, Hume DA: Murine DEP-1, a receptor protein tyrosine phosphatase, is expressed in macrophages and is regulated by CSF-1 and LPS. J Leukoc Biol. 1998, 64: 692-701.PubMed
30.
Lichanska AM, Hume DA: Origins and functions of phagocytes in the embryo. Exp Hemat. 2000, 28: 601-611. 10.1016/S0301-472X(00)00157-0.CrossRefPubMed
31.
Osborne JM, den Elzen N, Lichanska AM, Costelloe EO, Yamada T, Cassady AI, Hume DA: Murine DEP-1, a receptor protein tyrosine phosphatase, is expressed in macrophages and is regulated by CSF-1 and LPS. J Leukoc Biol. 1998, 64: 692-701.PubMed
32.
Baker JE, Majeti R, Tangye SG, Weiss A: Protein tyrosine phosphatase CD148-mediated inhibition of T-cell receptor signal transduction is associated with reduced LAT and phospholipase C gamma 1 phosphorylation. Mol Cell Biol. 2001, 21: 2393-2403. 10.1128/MCB.21.7.2393-2403.2001.PubMedCentralCrossRefPubMed
33.
Lin J, Weiss A: The tyrosine phosphatase CD148 is excluded from the immunologic synapse and down-regulates prolonged T cell signaling. J Cell Biol. 2003, 162: 673-682. 10.1083/jcb.200303040.PubMedCentralCrossRefPubMed
34.
Charpentier X, Gabay JE, Reyes M, Zhu JW, Weiss A, Shuman HA: Chemical genetics reveals bacterial and host cell functions critical for type IV effector translocation by Legionella pneumophila. PLoS Pathogens. 2009, 5: e1000501-10.1371/journal.ppat.1000501.PubMedCentralCrossRefPubMed
35.
Zhu JW, Doan K, Park J, Chau AH, Zhang H, Lowell CA, Weiss A: Receptor-like tyrosine phosphatases CD45 and CD148 have distinct functions in chemoattractant-mediated neutrophil migration and response to S. aureus. Immunity. 2011, 35: 757-769. 10.1016/j.immuni.2011.09.011.PubMedCentralCrossRefPubMed
36.
Burman A, Haworth O, Hardie DL, Amft EN, Siewert C, Jackson DG, Salmon M, Buckley CD: A chemokine-dependent stromal induction mechanism for aberrant lymphocyte accumulation and compromised lymphatic return in rheumatoid arthritis. J Immunol. 2005, 174: 1693-1700.PubMedCentralCrossRefPubMed
37.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324. 10.1002/art.1780310302.CrossRefPubMed
38.
Cook AD, Turner AL, Braine EL, Pobjoy J, Lenzo JC, Hamilton JA: Regulation of systemic and local myeloid cell subpopulations by bone marrow cell-derived granulocyte-macrophage colony-stimulating factor in experimental inflammatory arthritis. Arthritis Rheum. 2011, 63: 2340-2351. 10.1002/art.30354.CrossRefPubMed
39.
Campbell IK, Bendele A, Smith DA, Hamilton JA: Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice. Ann Rheum Dis. 1997, 56: 364-368. 10.1136/ard.56.6.364.PubMedCentralCrossRefPubMed
40.
Cook AD, De Nardo CM, Braine EL, Turner AL, Vlahos R, Way KJ, Beckman SK, Lenzo JC, Hamilton JA: Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement. Arthritis Res Ther. 2010, 12: R37-10.1186/ar2946.PubMedCentralCrossRefPubMed
41.
Cook AD, Pobjoy J, Sarros S, Steidl S, Durr M, Lacey DC, Hamilton JA: Granulocyte-macrophage colony-stimulating factor is a key mediator in inflammatory and arthritic pain. Ann Rheum Dis. 2013, 72: 265-270. 10.1136/annrheumdis-2012-201703.CrossRefPubMed
42.
Cook AD, Tumer AL, Braine EL, Hume DA, Hamilton JA: T cells are the source of GM-CSF required for collagen-induced arthritis induction. Arthritis Rheum. 2006, 54: S593-S593. 10.1002/art.21630.CrossRef
43.
Monach PA, Mathis D, Benoist C: The K/BxN arthritis model. Current protocols in immunology/edited by John E Coligan [et al]. 2008, Chapter 15: Unit 15.22
44.
Kyburz D, Corr M: The KRN mouse model of inflammatory arthritis. Springer Semin Immunopath. 2003, 25: 79-90. 10.1007/s00281-003-0131-5.CrossRef
45.
Pettit AR, Walsh NC, Manning C, Goldring SR, Gravallese EM: RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology. 2006, 45: 1068-1076. 10.1093/rheumatology/kel045.CrossRefPubMed
46.
Rider DA, Young SP: Measuring the specific activity of the CD45 protein tyrosine phosphatase. J Immunol Methods. 2003, 277: 127-134. 10.1016/S0022-1759(03)00181-9.CrossRefPubMed
47.
Ruivenkamp CAL, van Wezel T, Zanon C, Stassen APM, Vlcek C, Csikos T, Klous AM, Tripodis N, Perrakis A, Boerrigter L, Groot PC, Lindeman J, Mooi WJ, Meijjer GA, Scholten G, Dauwerse H, Paces V, van Zandwijk N, van Ommen GJ, Demant P: Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. Nat Genet. 2002, 31: 295-300. 10.1038/ng903.CrossRefPubMed
48.
Trapasso F, Iuliano R, Boccia A, Stella A, Visconti R, Bruni P, Baldassarre G, Santoro M, Viglietto G, Fusco A: Rat protein tyrosine phosphatase eta suppresses the neoplastic phenotype of retrovirally transformed thyroid cells through the stabilization of p27(Kip1). Mol Cell Biol. 2000, 20: 9236-9246. 10.1128/MCB.20.24.9236-9246.2000.PubMedCentralCrossRefPubMed
49.
Salmon M, Gaston JSH: The role of T lymphocytes in rheumatoid arthritis. Br Med Bull. 1995, 51: 332-345.PubMed
50.
Buckley CD, Amft N, Bradfield PF, Pilling D, Ross E, Arenzana-Seisdedos F, Amara A, Curnow SJ, Lord JM, Scheel-Toellner D, Salmon M: Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol. 2000, 16: 3423-3429.CrossRef
51.
Meng TC, Fukada T, Tonks NK: Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell. 2002, 9: 387-399. 10.1016/S1097-2765(02)00445-8.CrossRefPubMed
52.
Autschbach F, Palou E, Mechtersheimer G, Rohr C, Pirotto F, Gassler N, Otto HF, Schraven B, Gaya A: Expression of the membrane protein tyrosine phosphatase CD148 in human tissues. Tissue Antigens. 1999, 54: 485-498. 10.1034/j.1399-0039.1999.540506.x.CrossRefPubMed
53.
Lunardi C, Bason C, Leandri M, Navone R, Lestani M, Millo E, Benatti U, Cilli M, Beri R, Corrocher R, Puccetti A: Autoantibodies to inner ear and endothelial antigens in Cogan's syndrome. Lancet. 2002, 360: 915-921. 10.1016/S0140-6736(02)11028-2.CrossRefPubMed
54.
Frame MC: Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta. 2002, 1602: 114-130.PubMed
55.
56.
Thomas ML, Lefrancois L: Differential expression of the leukocyte common antigen family. Immunol Today. 1988, 9: 320-326. 10.1016/0167-5699(88)91326-6.CrossRefPubMed
57.
Cale CM, Klein NJ, Novelli V, Veys P, Jones AM, Morgan G: Severe combined immunodeficiency with abnormalities in expression of the common leucocyte antigen, CD45. Arch Dis Child. 1997, 76: 163-164. 10.1136/adc.76.2.163.PubMedCentralCrossRefPubMed
58.
Kishihara K, Penninger J, Wallace VA, Kundig TM, Kawai K, Wakeham A, Timms E, Pfeffer K, Ohashi PS, Thomas ML, Furlonger C, Paige CJ, Mak TW: Normal B cell development but impaired T cell development in CD46-exon 6 protein tyrosine phosphatase deficient mice. Cell. 1993, 74: 143-156. 10.1016/0092-8674(93)90302-7.CrossRefPubMed
59.
Takahashi K, Mernaugh RL, Friedman DB, Weller R, Tsuboi N, Yamashita H, Quaranta V, Takahashi T: Thrombospondin-1 acts as a ligand for CD148 tyrosine phosphatase. Proc Natl Acad Sci USA. 2012, 109: 1985-1990. 10.1073/pnas.1106171109.PubMedCentralCrossRefPubMed
60.
Whiteford JR, Xian X, Chaussade C, Vanhaesebroeck B, Nourshargh S, Couchman JR: Syndecan-2 is a novel ligand for the protein tyrosine phosphatase receptor CD148. Mol Biol Cell. 2011, 22: 3609-3624. 10.1091/mbc.E11-02-0099.PubMedCentralCrossRefPubMed
61.
Patterson AM, Cartwright A, David G, Fitzgerald O, Bresnihan B, Ashton BA, Middleton J: Differential expression of syndecans and glypicans in chronically inflamed synovium. Ann Rheum Dis. 2008, 67: 592-601.PubMedCentralCrossRefPubMed
62.
Gotis-Graham I, Hogg PJ, McNeil HP: Significant correlation between thrombospondin 1 and serine proteinase expression in rheumatoid synovium. Arthritis Rheum. 1997, 40: 1780-1787. 10.1002/art.1780401009.CrossRefPubMed
Metadata
Title
Differential expression of CD148 on leukocyte subsets in inflammatory arthritis
Authors
Richa K Dave
Amy J Naylor
Stephen P Young
Rachel Bayley
Debbie L Hardie
Oliver Haworth
David A Rider
Andrew D Cook
Christopher D Buckley
Stuart Kellie
Publication date
01-10-2013
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 5/2013
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar4288

Other articles of this Issue 5/2013

Arthritis Research & Therapy 5/2013 Go to the issue

Research article

Arterial hypertension assessed “out-of-office” in a contemporary cohort of rheumatoid arthritis patients free of cardiovascular disease is characterized by high prevalence, low awareness, poor control and increased vascular damage-associated “white coat” phenomenon

Research article

GREM1, FRZB and DKK1 mRNA levels correlate with osteoarthritis and are regulated by osteoarthritis-associated factors

Research article

The influence of cathelicidin LL37 in human anti-neutrophils cytoplasmic antibody (ANCA)-associated vasculitis

Research article

Interleukin-17A- or tumor necrosis factor α-mediated increase in proliferation of T cells cocultured with synovium-derived mesenchymal stem cells in rheumatoid arthritis

Research article

TNF receptor-associated factor 5 gene confers genetic predisposition to acute anterior uveitis and pediatric uveitis

Research article

CD56+ monocytes have a dysregulated cytokine response to lipopolysaccharide and accumulate in rheumatoid arthritis and immunosenescence
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits